Other Clinical Trial - PErfusioN, OxyGen ConsUmptIon & ENergetics in ADPKD

Status Completed

Clinical Trial Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials. The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04407481
Study type	Observational
Source	University of Colorado, Denver
Contact
Status	Completed
Phase
Start date	November 1, 2020
Completion date	October 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04310319` - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt	N/A
Completed	`NCT04363554` - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease	N/A
Recruiting	`NCT05521191` - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease	Phase 1
Completed	`NCT03687554` - Effect of Venglustat in Patients With Renal Impairment	Phase 1
Terminated	`NCT03523728` - A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients	Phase 2/Phase 3
Completed	`NCT00565097` - Lanreotide as Treatment of Polycystic Livers	Phase 2/Phase 3
Completed	`NCT00410007` - The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease	N/A
Completed	`NCT02251275` - Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease	Phase 3
Completed	`NCT01559363` - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease	Phase 1/Phase 2
Completed	`NCT02903511` - Feasibility Study of Metformin Therapy in ADPKD	Phase 2
Completed	`NCT00456365` - Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Phase 3
Recruiting	`NCT05510115` - Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease	Phase 2
Completed	`NCT02494141` - Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD	Phase 4
Completed	`NCT02847624` - Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed	`NCT03342742` - Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	N/A
Completed	`NCT02656017` - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease	Phase 2
Completed	`NCT04023214` - The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Terminated	`NCT01589705` - The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease	N/A
Completed	`NCT00426153` - Octreotide in Severe Polycystic Liver Disease	Phase 2/Phase 3
Completed	`NCT04534985` - Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) — PENGUIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms